ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for albuterol sulfate; ipratropium bromide and what is the scope of patent protection?
Albuterol sulfate; ipratropium bromide
is the generic ingredient in four branded drugs marketed by Boehringer Ingelheim, Apotex Inc, Cipla, Fosun Pharma, Luoxin Aurovitas, Nephron, Ritedose Corp, Sun Pharm, Teva Pharms, Watson Labs Teva, and Mylan Speciality Lp, and is included in twelve NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Albuterol sulfate; ipratropium bromide has one hundred and eighteen patent family members in thirty-six countries.
Fifteen suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
International Patents: | 118 |
US Patents: | 6 |
Tradenames: | 4 |
Applicants: | 11 |
NDAs: | 12 |
Finished Product Suppliers / Packagers: | 15 |
Clinical Trials: | 4 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE |
DailyMed Link: | ALBUTEROL SULFATE; IPRATROPIUM BROMIDE at DailyMed |
Recent Clinical Trials for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
James J. Peters Veterans Affairs Medical Center | Phase 2 |
University of Texas Southwestern Medical Center | Phase 4 |
Dey | Phase 3 |
See all ALBUTEROL SULFATE; IPRATROPIUM BROMIDE clinical trials
Generic filers with tentative approvals for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Applicant | Application No. | Strength | Dosage Form |
⤷ Try a Trial | ⤷ Try a Trial | EQ 0.083% BASE;0.017% | SOLUTION;INHALATION |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Drug Class | Anticholinergic beta2-Adrenergic Agonist |
Mechanism of Action | Adrenergic beta2-Agonists Cholinergic Antagonists |
Paragraph IV (Patent) Challenges for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
COMBIVENT RESPIMAT | Inhalation Aerosol | albuterol sulfate; ipratropium bromide | 100 mcg/20 mcg per actuation | 021747 | 1 | 2023-03-30 |
US Patents and Regulatory Information for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Expired US Patents for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
International Patents for ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | 490823 | ⤷ Try a Trial | |
Japan | 4411209 | ⤷ Try a Trial | |
Slovenia | 1539368 | ⤷ Try a Trial | |
Eurasian Patent Organization | 008630 | УСТРОЙСТВО ДЛЯ КРЕПЛЕНИЯ СТРУЙНОЙ ДЕТАЛИ (DEVICE FOR HOLDING A FLUIDIC COMPONENT) | ⤷ Try a Trial |
Germany | 502004005733 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.